Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1136071

COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?


Rnjak, Dina; Ravlić, Sanda; Šola, Ana-Marija; Halassy, Beata; Šemnički, Joško; Šuperba, Martina; Hećimović, Ana; Kurolt, Ivan-Christian; Kurtović, Tihana; Mačak Šafranko, Željka et al.
COVID-19 convalescent plasma as long-term therapy in immunodeficient patients? // Transfusion clinique et biologique (2021) doi:10.1016/j.tracli.2021.04.004 (znanstveni, prihvaćen)


CROSBI ID: 1136071 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?

Autori
Rnjak, Dina ; Ravlić, Sanda ; Šola, Ana-Marija ; Halassy, Beata ; Šemnički, Joško ; Šuperba, Martina ; Hećimović, Ana ; Kurolt, Ivan-Christian ; Kurtović, Tihana ; Mačak Šafranko, Željka ; Polančec, Denis ; Bendelja, Krešo ; Mušlin, Tatjana ; Jukić, Irena ; Vuk, Tomislav ; Zenić, Lucija ; Artuković, Marinko

Vrsta, podvrsta
Radovi u časopisima, znanstveni

Izvornik
Transfusion clinique et biologique (2021)

Status rada
Prihvaćen

Ključne riječi
COVID-19 ; convalescent plasma ; immunodeficiency ; infective virus-neutralization assay ; neutralizing antibody ; SARS-CoV-2

Sažetak
Abstract Objectives: The patients with hematological malignancies are a vulnerable group to COVID-19, due to the immunodeficiency resulting from the underlying disease and oncological treatment that significantly impair cellular and humoral immunity. Here we report on a beneficial impact of a passive immunotherapy with convalescent plasma to treat a prolonged, active COVID-19 infection in a patient with a history of nasopharyngeal diffuse large B-cell lymphoma treated with the therapy inducing substantial impairment of particularly humoral arm of immune system. The specific aim was to quantify SARS-CoV2 neutralizing antibodies in a patient plasma during the course of therapy. Materials and methods: Besides the standard of care treatment and monitoring, neutralizing antibody titers in patient's serum samples, calibrated according to the First WHO International Standard for anti- SARS-CoV-2 immunoglobulin (human), were quantified in a time- dependent manner. During the immunotherapy period peripheral blood flow cytometry immunophenotyping was conducted to characterize lymphocyte subpopulations. Results: The waves of clinical improvements and worsening coincided with transfused neutralizing antibodies rises and drops in the patient's systemic circulation, proving their contribution in controlling the disease progress. Besides the patient's lack of own humoral immune system, immunophenotyping analysis revealed also the reduced level of helper T-lymphocytes and immune exhaustion of monocytes. Conclusion: Therapeutic approach based on convalescent plasma transfusion transformed a prolonged, active COVID-19 infection into a manageable chronic disease.

Izvorni jezik
Engleski

Znanstvena područja
Biologija, Interdisciplinarne prirodne znanosti, Kliničke medicinske znanosti, Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)



POVEZANOST RADA


Ustanove:
Klinika za infektivne bolesti "Dr Fran Mihaljević",
Hrvatski zavod za transfuzijsku medicinu,
Dječja bolnica Srebrnjak,
Sveučilište u Zagrebu

Citiraj ovu publikaciju

Rnjak, Dina; Ravlić, Sanda; Šola, Ana-Marija; Halassy, Beata; Šemnički, Joško; Šuperba, Martina; Hećimović, Ana; Kurolt, Ivan-Christian; Kurtović, Tihana; Mačak Šafranko, Željka et al.
COVID-19 convalescent plasma as long-term therapy in immunodeficient patients? // Transfusion clinique et biologique (2021) doi:10.1016/j.tracli.2021.04.004 (znanstveni, prihvaćen)
Rnjak, D., Ravlić, S., Šola, A., Halassy, B., Šemnički, J., Šuperba, M., Hećimović, A., Kurolt, I., Kurtović, T. & Mačak Šafranko, Ž. (2021) COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?. Prihvaćen za objavljivanje u Transfusion clinique et biologique. [Preprint] doi:10.1016/j.tracli.2021.04.004.
@unknown{unknown, year = {2021}, DOI = {10.1016/j.tracli.2021.04.004}, keywords = {COVID-19, convalescent plasma, immunodeficiency, infective virus-neutralization assay, neutralizing antibody, SARS-CoV-2}, journal = {Transfusion clinique et biologique}, doi = {10.1016/j.tracli.2021.04.004}, title = {COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?}, keyword = {COVID-19, convalescent plasma, immunodeficiency, infective virus-neutralization assay, neutralizing antibody, SARS-CoV-2} }
@unknown{unknown, year = {2021}, DOI = {10.1016/j.tracli.2021.04.004}, keywords = {COVID-19, convalescent plasma, immunodeficiency, infective virus-neutralization assay, neutralizing antibody, SARS-CoV-2}, journal = {Transfusion clinique et biologique}, doi = {10.1016/j.tracli.2021.04.004}, title = {COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?}, keyword = {COVID-19, convalescent plasma, immunodeficiency, infective virus-neutralization assay, neutralizing antibody, SARS-CoV-2} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font